185 related articles for article (PubMed ID: 24402882)
1. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.
Wheeler AJ; Feetam CL; Harrison J
Clin Drug Investig; 2014 Mar; 34(3):203-11. PubMed ID: 24402882
[TBL] [Abstract][Full Text] [Related]
2. Patterns of clozapine prescribing in a mental health service in New Zealand.
Harrison J; Janlöv M; Wheeler AJ
Pharm World Sci; 2010 Aug; 32(4):503-11. PubMed ID: 20526811
[TBL] [Abstract][Full Text] [Related]
3. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
4. Ethnic comparisons of antipsychotic use in schizophrenia.
Wheeler A; Humberstone V; Robinson E
Aust N Z J Psychiatry; 2008 Oct; 42(10):863-73. PubMed ID: 18777230
[TBL] [Abstract][Full Text] [Related]
5. Impact of audit and feedback on antipsychotic prescribing in schizophrenia.
Wheeler A; Humberstone V; Robinson E; Sheridan J; Joyce P
J Eval Clin Pract; 2009 Jun; 15(3):441-50. PubMed ID: 19366393
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.
McMillan SS; Jacobs S; Wilson L; Theodoros T; Robinson G; Anderson C; Mihala G; Wheeler AJ
BMC Psychiatry; 2017 Apr; 17(1):139. PubMed ID: 28407747
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic prescribing and its correlates in New Zealand.
Dey S; Menkes DB; Obertova Z; Chaudhuri S; Mellsop G
Australas Psychiatry; 2016 Aug; 24(4):360-4. PubMed ID: 26819405
[TBL] [Abstract][Full Text] [Related]
8. Outcomes for schizophrenia patients with clozapine treatment: how good does it get?
Wheeler A; Humberstone V; Robinson G
J Psychopharmacol; 2009 Nov; 23(8):957-65. PubMed ID: 18635713
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
10. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
Martínez-Andrés JA; García-Carmona JA
Int Clin Psychopharmacol; 2020 May; 35(3):163-169. PubMed ID: 31851035
[TBL] [Abstract][Full Text] [Related]
11. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand.
Humberstone V; Wheeler A; Lambert T
Aust N Z J Psychiatry; 2004 Apr; 38(4):240-5. PubMed ID: 15038803
[TBL] [Abstract][Full Text] [Related]
12. Trends in antipsychotic prescribing in schizophrenia in Auckland.
Wheeler A; Humberstone V; Robinson G
Australas Psychiatry; 2006 Jun; 14(2):169-74. PubMed ID: 16734645
[TBL] [Abstract][Full Text] [Related]
13. The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study.
Siskind D; Reddel T; MacCabe JH; Kisely S
Psychopharmacology (Berl); 2019 Jun; 236(6):1931-1935. PubMed ID: 30715572
[TBL] [Abstract][Full Text] [Related]
14. Clozapine prescribing in a Canadian outpatient population.
Alessi-Severini S; Le Dorze JA; Nguyen D; Honcharik P; Eleff M
PLoS One; 2013; 8(12):e83539. PubMed ID: 24358290
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
[TBL] [Abstract][Full Text] [Related]
16. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital.
Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M
CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766
[TBL] [Abstract][Full Text] [Related]
17. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
18. Explicit review of risperidone long-acting injection prescribing practice.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
[TBL] [Abstract][Full Text] [Related]
19. Clozapine Use in a Cohort of First-Episode Psychosis.
Doyle R; Behan C; OʼKeeffe D; Masterson S; Kinsella A; Kelly A; Sheridan A; Keating D; Hynes C; Madigan K; Lawlor E; Clarke M
J Clin Psychopharmacol; 2017 Oct; 37(5):512-517. PubMed ID: 28650930
[TBL] [Abstract][Full Text] [Related]
20. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.
Taylor DM; Young C; Paton C
J Clin Psychiatry; 2003 Jan; 64(1):30-4. PubMed ID: 12590620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
